Background--Elevated high-sensitivity C-reactive protein (hsCRP) has been associated with increased risks of adverse outcomes of various cardiovascular diseases. The relationship between hsCRP and the prognosis of hypertrophic cardiomyopathy remains to be evaluated.
H ypertrophic cardiomyopathy (HCM) is one of the most common monogenic inherited cardiovascular diseases. 1 The disease affects all age groups, with marked clinical heterogeneity, ranging from a normal lifespan without symptoms to poor outcomes such as sudden cardiac death (SCD), advanced heart failure, or stroke. 2, 3 Although several factors have been proposed for risk stratification in patients with HCM, including family history of sudden death, unexplained syncope, degree of left ventricular wall thickness, resting left ventricular outflow tract obstruction, nonsustained ventricular tachycardia, and congestive symptoms, the clinical outcomes of HCM are still largely unpredictable. 1, 4, 5 Inflammation is a well-established risk factor for the development of cardiovascular disease. 6 Currently, C-reactive protein level, a nonspecific inflammatory marker, 7 has been associated with adverse events in various cardiovascular diseases, including myocardial infarction, 6, 8 heart failure, 9, 10 ischemic stroke, 6, 11 atrial fibrillation, 12,13 type 2 diabetes mellitus, 14, 15 and hypertension. 16 A previous study showed that the plasma level of high-sensitivity C-reactive protein (hsCRP) was higher in patients with HCM. 17 These findings provide evidence that the plasma levels of hsCRP are closely involved in the development of HCM clinical outcomes. However, the prognostic significance of hsCRP in the clinical outcomes of HCM remains to be evaluated.
Methods

Study Population
The study used an observational cohort methodology. In total, 543 subjects were invited to participate in the study at Fuwai Hospital from 2001 to 2011. Patients with autoimmune or inflammatory disease (6 patients), active infections (1 patient), and cancer (2 patients) were excluded. Forty-four patients (8.2%) were lost during follow-up in the study (the baseline characteristics of the 44 patients with HCM according to risk category of hsCRP are listed in Table S1 . The final study subjects consisted of 490 patients ( Figure S1 ). HCM was ascertained by an unexplained maximal left ventricle wall thickness ≥15 mm on echocardiography and/or cardiac magnetic resonance imaging in the absence of other cardiac or systemic diseases capable of producing that magnitude of hypertrophy. 1, 3 All of the patients gave informed consent to participate in this study, which was approved by the ethics committee of Fuwai Hospital. This observational cohort study was performed in keeping with the requirements of the Declaration of Helsinki.
Clinical Data Collection
The data of baseline characteristics and clinical outcomes of patients with HCM were prospectively collected with prospectively designed data forms by experienced physicians. Finally, the data were entered into the network database (Likang Times Technology Co. Ltd, Beijing, China). The twice-entry method was used for data entry. When the values of the 2 entries were consistent, the data would enter the database. Otherwise, the system would automatically flag an error, and it could then be corrected by checking the raw data. Twice data entry of the same sample was performed by different people.
HsCRP Measurement
Baseline blood samples were obtained at enrollment. After collection, the blood samples were rapidly centrifuged at 1800 g for 10 minutes and the separated plasma samples were immediately stored at À70°C until analysis. The plasma level of hsCRP was measured using the Immunoturbidimetric Assay (Orion Diagnostica, Finland). All measurements were performed in the laboratory at Fuwai Hospital.
Clinical Outcomes
The end points of this study were cardiovascular death and allcause mortality. The cardiovascular death included SCD, heart failure-related death, and stroke-related death. SCD was defined as witnessed, unexpected, and instantaneous collapse leading to death within 1 hour of the onset of symptoms. Death related to heart failure was defined as death preceded by symptoms of heart failure >1 hour.
Statistical Analysis
Participants were divided into 3 groups according to risk category of hsCRP (low hsCRP group <1.0 mg/L, median hsCRP group 1.0-3.0 mg/L, high hsCRP group >3.0 mg/L) 18 or according to tertiles of hsCRP level. The baseline characteristics among the 3 groups were analyzed by ANOVA for parametric variables, the Kruskal-Wallis test for nonparametric variables, and the v 2 test for categorical variables. Survival estimates were calculated by the Kaplan-Meier method and the log-rank test was used for comparison. The association between hsCRP and development of adverse outcomes of HCM were estimated with univariate and multivariate Cox proportional hazards regression models. Model 1 was unadjusted. Model 2 was adjusted for age, sex, and New York Heart Association (NYHA) class III/IV. Model 3 adjusted for age, sex, NYHA class III/IV, family history of SCD, unexplained syncope, resting left ventricular outflow tract obstruction, maximal left ventricular wall thickness, and nonsustained ventricular tachycardia. Multivariable models were fitted using backward elimination of nonsignificant factors at a 10% level. Furthermore, we also used hsCRP as a continuous variable to examine the association between hsCRP and the risk of adverse outcomes. A receiver operating characteristic (ROC) curve was generated to evaluate the accuracy of hsCRP in the prediction of adverse outcomes. All statistical testing was 2-sided. Results were considered statistically significant at a level of P<0.05. All analyses were performed with PASW Statistics 18.0 software (SPSS Inc, Chicago, IL).
Results
Baseline Characteristics
The baseline characteristics of the 490 patients with HCM according to risk category of hsCRP are listed in Table 1 In addition, the differences among the 3 groups according to tertiles of hsCRP were similar to the risk category of hsCRP (Table S2) .
Survival Analysis
During the follow-up of 3.7AE2.0 years, there were 30 (6.1%) cardiovascular deaths, including SCD in 11 patients, heart Table S3 . During follow-up, the rate of cardiovascular death in the high hsCRP group, median hsCRP group, and low hsCRP group were 13.5% (15/111), 5.6% (10/178), and 2.5% (5/201) (P<0.001), respectively. According to the risk category of hsCRP, survival free of cardiovascular death was lower in the high hsCRP group (log-rank P<0.001, Figure 1A ). Similarly, 38 (7.8%) of the 490 patients had all-cause mortality. Subjects in the high hsCRP group had lower all-cause mortality-free survival (log-rank P<0.001, Figure 1B ). Furthermore, survival free of SCD and heart failure-related death were lower in the high hsCRP group (log-rank P=0.005, Figure 2A ; log-rank P=0.008, Figure 2B , respectively). There were 5 strokerelated deaths during the follow-up. The incidence of strokerelated deaths was low and did not allow for further analysis. Subjects in the higher hsCRP group showed significantly lower 3-year survival rates of cardiovascular death and allcause mortality (Table S4 ) and showed significantly higher Figure 1 . Survival free of cardiovascular death (A) and all-cause mortality (B) in patients with HCM. According to risk category of hsCRP, subjects in the high hsCRP group had lower cardiovascular death and all-cause mortalityfree survival in the patients with HCM. P-values were calculated using the log-rank test. HCM indicates hypertrophic cardiomyopathy; hsCRP, high-sensitivity C-reactive protein. According to the risk category of hsCRP, subjects in the high hsCRP group had lower sudden cardiac death and heart failure-related death-free survival than in the patients with HCM. P-values were calculated using the log-rank test. HCM indicates hypertrophic cardiomyopathy; hsCRP, high-sensitivity C-reactive protein.
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Relation of hsCRP to Adverse Outcomes
To further evaluate the effect of hsCRP on development of adverse outcomes of HCM, we used univariate and multivariate Cox proportional hazards regression models to reveal whether the plasma hsCRP level could predict the adverse outcomes of patients with HCM. In univariable Cox regression models (Model 1), compared with patients in the low hsCRP group, the hazard ratios (HR) for cardiovascular deaths in the median hsCRP group and high hsCRP group were 2.32 (95% CI 0.79-6.80, P=0.124) and 5.88 (95% CI 2.13-16.20, P=0.001), respectively. Similarly, the high hsCRP group had a higher risk of developing all-cause mortality than the low hsCRP group (HR 5.04, 95% CI 2.10-12.09, P<0.001). There was no significant difference in relative risk of all-cause mortality between the low hsCRP group and the median hsCRP group (HR 2.16, 95% CI 0.86-5.42, P=0.101). Furthermore, compared with patients in the low hsCRP group, the HR for SCD and heart failurerelated death in the high hsCRP group were 12 Table 2 ). In addition, when divided into 3 groups according to tertiles of hsCRP, the survival analysis and multivariate Cox regression analysis were similar to the risk category of hsCRP, which shows that elevated levels of hsCRP predict high risk of adverse outcomes in patients with HCM (Figures S2 and S3 
Prognostic Value of hsCRP for Adverse Outcomes
The ROC analysis indicated that hsCRP had reasonable accuracy for prediction of adverse outcomes. The area under the ROC curve was 0.71 (95% CI 0.62-0.80, P<0.001) for cardiovascular death (Figure 3) . A cutoff of hsCRP >3.0 mg/L had a 96.0% negative predictive value for predicting cardiovascular death (Table S7 ). The area under the ROC curve was 0.70 for all-cause mortality (95% CI 0.62-0.79, P<0.001), 0.77 for SCD (95% CI 0.64-0.89, P=0.002), and 0.69 for heart failure-related death (95% CI 0.54-0.84, P=0.017) ( Figure S4 ).
Discussion
In this study, we found that elevated hsCRP was associated with adverse outcomes in patients with HCM. Patients in the high hsCRP group had higher risk for cardiovascular death, as well as all-cause mortality, SCD, and heart failure-related death. Furthermore, when analyzed as a continuous variable, elevated hsCRP predicted increased risk for adverse outcomes in patients with HCM. The ROC analysis indicated that hsCRP had reasonable predictive accuracy for the development of adverse outcomes.
CRP measured by a highly sensitive assay (hsCRP) has considerable chemical stability, requires no special precautions for sampling, and has a relatively long half-life. 19 Therefore, it has emerged as a leading biomarker of inflammation for clinical application. HsCRP has been regarded as a traditional risk factor in cardiovascular diseases. 20 A previous study found that obstructive HCM was associated with increased CRP levels, compared with nonobstructive HCM. 21 Similarly, the plasma level of hsCRP was significantly higher in patients with obstructive HCM than nonobstructive HCM in this study. However, the prognostic value of hsCRP in HCM has not yet been reported. To our knowledge, this is the first study to demonstrate that hsCRP was an independent predictor of adverse prognosis in patients with HCM. Histological studies support a possible association between inflammation and HCM, and infiltration of chronic inflammatory cells is found in the myocardium of patients with HCM. 22, 23 Recently, the study has demonstrated that a lowgrade inflammatory response may play a significant role in the phenotypic expression of myocardial fibrosis in HCM. 17 Previous studies found that CRP may have a pathogenic role in the development of cardiac hypertrophy and fibrosis, possibly through the nuclear factor kappa B signaling pathways. 24 Zhang et al also found that activation of the nuclear factor kappa B signaling pathways may be the mechanisms by which CRP promotes cardiac fibrosis.
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Myocardial fibrosis is a hallmark of hypertrophic cardiomyopathy. It is an early manifestation of HCM even before hypertrophic remodeling. 26 Meanwhile, myocardial fibrosis is a major determinant of SCD, ventricular tachyarrhythmia, left ventricular dysfunction, and heart failure. [26] [27] [28] Our results showed that elevated hsCRP predicted an increased risk for adverse outcomes in patients with HCM. These studies suggest that prolonged and low-grade myocardial inflammation induces nuclear factor kappa B upregulation and activates inflammatory cell invasion and fibroblasts, and finally leads to myocardial fibrosis. 17, 25, 29, 30 Myocardial fibrosis is thought to play a significant role in clinical progression. In the present study, the event rates were 7.8% (2.12 per 100 person-year) for all-cause mortality and 6.1% (1.67 per 100 person-year) for cardiovascular deaths. Recently, Maron et al have shown that the event rate was 8.2% (1.16 per 100 person-year) for all-cause mortality and 4.0% (0.53 per 100 person-year) for HCM-related death (7.2AE5.2 years of follow-up). 31 Another study shows that the event rate of allcause mortality was 13.1% and HCM-related death was 3.7% (6.6AE5.3 years of follow-up). 32 Compared with these studies, the event rates of cardiovascular deaths in our study were somewhat higher. In other studies, Coats et al showed an event rate of all-cause mortality of 8% (68/847) (a median duration of 3.5 years of follow-up), 33 and Geske et al showed that the incidence per 100 person-year of all-cause mortality was 2.29. 34 The event rates of our study were comparable to these reports. The discrepancy of event rates among different studies may be due to the collection bias of patients, or ethnic differences. In our study, all included patients were of the Chinese Han ethnic group, and their disease may be more severe because the Fuwai Hospital is the National Center for Cardiovascular Diseases. In spite of the above, our results are still able to clearly indicate that hsCRP is a risk factor of adverse outcomes in patients with HCM.
In this study, we found that patients with higher hsCRP levels had a higher risk for adverse outcomes of HCM. Although a causal relationship between hsCRP and the prognosis of HCM had not yet been established, our findings suggest a possible association of an inflammatory state and the clinical progression of HCM.
The patients enrolled in this study come from a single center and were limited to the native Chinese population. There were 8.2% of patients lost during follow-up in the present study, which might introduce biases. In addition, the values of hsCRP were measured at enrollment. We did not have serial measurements of hsCRP in this study. These facts limit the generalizability of our findings.
Conclusions
Our results indicate that elevated plasma hsCRP is associated with increased risk for adverse outcomes in the patients with HCM. Although a causal relationship between hsCRP and the prognosis of HCM had not yet been established, our findings suggest a possible association of an inflammatory state and the clinical progression of HCM. Abbreviations: AF= atrial fibrillation; BMI= body mass index; CHD= coronary heart disease; HCM= hypertrophic cardiomyopathy; hsCRP= high-sensitivity C-reactive protein; ICD= implantable cardioverter-defibrillator; LV= left ventricular; LVOT= left ventricular 
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